Feed / ALMS

Alumis Inc.

ALMS

Healthcare · 24.22 +5.9% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Alumis Inc.'s move is being confirmed by its market group.

ALMS accounts for 34.1% of the group's measured movement across 5.6 effective names. raw member direction is mixed; 7 of 12 session-normalized paths align to the upside. Capital-flow agreement is 16%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveDominant mover#1 of 12 by movement share
Group movement share34.1%Absolute path energy—not portfolio weight
Relative path+7.72%aligned
Effective breadth5.6 / 12balanced
Relative alignment7/12upside path · 1 counter-moving
Capital-flow agreement16%not yet clean
SEQUENCE READ

EWTX, AXSM moved materially before ALMS. ALMS crossed its material path threshold at 15:05 ET, 1395 minutes after the first measured mover. GPCR, PRAX, RCUS followed.

Operating margin-1886.9%latest annual period
EVIDENCE COVERAGE

10 of 16 members in Clinical Biopharmaceuticals are active. 0 of 3 disclosed connections are confirming.

What would change this read
  • At least 11 of 16 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as NBIX begins moving with the group.

Invalidation: The live read weakens if participation falls to 5 of 16 members or fewer.

Watch this read

Who this business touches

The relationships behind ALMS

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depended on by

PTGXProtagonist Therapeutics, Inc.competitorFeb 25, 2026 ▾

“Second-generation allosteric TYK2 inhibitors include zasocitinib (TAK-279, Takeda) and envudeucitinib (ESK-001, Alumis), which both reported positive Phase 3 results in late 2025 and early 2026, and are moving toward regulatory submissions for psoriasis and P…”

Filing peers

SYREORKAAKBA

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

ALMS is currently a Early Follower in the organic co-movement group Clinical Biopharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.